• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
5.71% $1.49

MESOBLAST LIMITED - Announcements

Market Cap $1.113B  ! watchlist Created with Sketch. Add to my watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MSBKey Manufacturing Agreement with FDA for Phase 3 TrialsPRICE SENSITIVE20/11/12
MSBMesoblast Market Update19/11/12
MSBPrice QueryPRICE SENSITIVE15/11/12
MSBCEO Presentation to Bell Potter Life Sciences Conference02/11/12
MSBAppendix 4C - quarterlyPRICE SENSITIVE31/10/12
MSBAppendix 3B31/10/12
MSBNotice of Annual General Meeting/Proxy Form29/10/12
MSBAnnual Report to shareholders29/10/12
MSB2012 Full Year Financial Results Presentation22/08/12
MSBStrong Cash Position to Further Diversify Product Pipeline22/08/12
MSBPreliminary Final ReportPRICE SENSITIVE22/08/12
MSBAppendix 4C - quarterlyPRICE SENSITIVE31/07/12
MSBRheumatoid Arthritis New Major Clinical Target for MSBPRICE SENSITIVE24/07/12
MSBResponse to ASXPrice QueryPRICE SENSITIVE18/06/12
MSBMSB Provides Corporate Strategy For Neurologic ProductPRICE SENSITIVE08/06/12
MSBFinal Director's Interest Notice16/05/12
MSBInitial Director's Interest Notice16/05/12
MSBDirector Appointment10/05/12
MSBAppendix 4C - quarterlyPRICE SENSITIVE30/04/12
MSBIntervertebral Disc Repair Phase 2 Trial UpdatePRICE SENSITIVE17/04/12
MSBMesoblast Update to Credit Suisse Asia Investment Conference26/03/12
MSBHalf Yearly Report and AccountsPRICE SENSITIVE27/02/12
MSB2012 Half Year Results Investor Presentation27/02/12
MSBFORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER22/02/12
MSBCompany Secretary Appointment/Resignation09/02/12
MSBAppendix 3B09/02/12
MSBFDA Clearance for Phase 2 Clinical Trial in Type 2 DiabetesPRICE SENSITIVE31/01/12
MSBAppendix 4C - quarterlyPRICE SENSITIVE12/01/12
MSBAppendix 3B12/01/12
MSBPresentation to 30th JP Morgan Healthcare Conference in USA12/01/12
MSBFORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER09/12/11
MSBResults of Meeting24/11/11
MSBCorporate Strategy Key to Mesoblast's Success24/11/11
MSBChairman's Address and CEO's Presentation to Shareholders24/11/11
MSBPositive Outcome From FDA Meeting For Diabetes ProgramPRICE SENSITIVE22/11/11
MSBPresentation to the American Heart Association15/11/11
MSBPositive Heart Failure Trial Results Presented to AHAPRICE SENSITIVE15/11/11
MSBPositive Results Using Adult Stem Cells for Type 2 DiabetesPRICE SENSITIVE10/11/11
MSBAppendix 4C - quarterlyPRICE SENSITIVE31/10/11
MSBResponse to ASX Price Query LetterPRICE SENSITIVE28/10/11
MSBAnnual Report to shareholders24/10/11
MSBNotice of Annual General Meeting/Proxy Form24/10/11
MSBClearance for First Phase 2 Clinical Trial for Eye DiseasesPRICE SENSITIVE24/10/11
MSBLicensing Executives Society Deals of Distinction AwardPRICE SENSITIVE20/10/11
MSBMSB and Lonza form strategic global manufacturing alliancePRICE SENSITIVE27/09/11
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER15/09/11
MSBFirst European Trial for Heart Attack Treatment ClearedPRICE SENSITIVE05/09/11
MSBFull Year Audited Statutory Accounts31/08/11
MSBMesoblast Management Presentation24/08/11
MSBMesoblast in Position of Considerable Strength24/08/11
MSBPreliminary Final ReportPRICE SENSITIVE24/08/11
MSBFirst Minimally Invasive Procedure for Lumbar Disc RepairPRICE SENSITIVE22/08/11
MSBHeart Failure Trial Selected for AHA Special Session15/08/11
MSBForm 604 - Notice of change of interests of substantial hold01/08/11
MSBAppendix 4C - quarterlyPRICE SENSITIVE01/08/11
MSBFDA Clearance for Phase 3 Bone Marrow Transplant TrialPRICE SENSITIVE07/07/11
MSBAppendix 3B06/07/11
MSBAmended Change of Director's Interest Notice04/07/11
MSBChange of Director's Interest Notice01/07/11
MSBFDA Clears Phase 2 Trial to Treat Degenerative Disc DiseasePRICE SENSITIVE29/06/11
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER22/06/11
MSBKey Product Franchises Featured at Nomura Asia Equity ForumPRICE SENSITIVE14/06/11
MSBRevascor Increases Blood Supply to Damaged Heart MusclePRICE SENSITIVE09/06/11
MSBMSB to Present at Goldman Sachs Global Healthcare Conference06/06/11
MSBKey USA Patents Increase Commercial Rights and IndicationsPRICE SENSITIVE24/05/11
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER04/05/11
MSBAppendix 4C - quarterlyPRICE SENSITIVE02/05/11
MSBSandP to remove Tower Australia Group from SP/ASX Indices18/04/11
MSBMesoblast Included in S and P/ASX 200 IndexPRICE SENSITIVE18/04/11
MSBAppendix 3B11/04/11
MSBMesoblast Update on Valeant Proposal to CephalonPRICE SENSITIVE07/04/11
MSBMesoblast Statement on Valeant Proposal to Cephalon31/03/11
MSBMesoblast CEO Named BioSpectrum Asia Person of the Year 201117/03/11
MSBAppendix 3B11/03/11
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER10/03/11
ACL +SandP Announces March SP/ASX Rebalance04/03/11
MSBAppendix 4D and Half Year Financial Report to 31 Dec 2010PRICE SENSITIVE28/02/11
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER17/02/11
MSBChange in substantial holding15/02/11
MSBCleansing Notice under Section 708A14/02/11
MSBMesoblast Issues New Equity to Cephalon, Increases Cash14/02/11
MSBSection 708AA Notice - Cleansing Statement11/02/11
MSBAppendix 3B11/02/11
MSBResults of Meeting09/02/11
MSBMesoblast EGM Speech and Presentation09/02/11
MSBAppendix 4C - Strong Cash PositionPRICE SENSITIVE31/01/11
MSBResponse to ASX Price QueryPRICE SENSITIVE13/01/11
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER13/01/11
MSBAlliance Highlighted at JP Morgan Healthcare Conference12/01/11
MSBCardiac Events, Mortality and Hospitalization ReducedPRICE SENSITIVE10/01/11
MSBNotice of Extraordinary General Meeting/Proxy Form07/01/11
MSBInitial Director's Interest Notice31/12/10
MSBChange of Director's Interest Notice30/12/10
MSBMesoblast Share Trading Policy Updated30/12/10
MSBChange in substantial holding29/12/10
MSBChange in substantial holding24/12/10
MSBChange of Director's Interest Notice24/12/10
MSBChange in substantial holding24/12/10
MSBFORM 603 INITIAL SUB FOLDER24/12/10
MSBSection 708AA Notice - Cleansing Statement23/12/10
MSBKey Manufacturing Agreement with FDA for Phase 3 Trials
20/11/12PRICE SENSITIVE
MSBMesoblast Market Update
19/11/12
MSBPrice Query
15/11/12PRICE SENSITIVE
MSBCEO Presentation to Bell Potter Life Sciences Conference
02/11/12
MSBAppendix 4C - quarterly
31/10/12PRICE SENSITIVE
MSBAppendix 3B
31/10/12
MSBNotice of Annual General Meeting/Proxy Form
29/10/12
MSBAnnual Report to shareholders
29/10/12
MSB2012 Full Year Financial Results Presentation
22/08/12
MSBStrong Cash Position to Further Diversify Product Pipeline
22/08/12
MSBPreliminary Final Report
22/08/12PRICE SENSITIVE
MSBAppendix 4C - quarterly
31/07/12PRICE SENSITIVE
MSBRheumatoid Arthritis New Major Clinical Target for MSB
24/07/12PRICE SENSITIVE
MSBResponse to ASXPrice Query
18/06/12PRICE SENSITIVE
MSBMSB Provides Corporate Strategy For Neurologic Product
08/06/12PRICE SENSITIVE
MSBFinal Director's Interest Notice
16/05/12
MSBInitial Director's Interest Notice
16/05/12
MSBDirector Appointment
10/05/12
MSBAppendix 4C - quarterly
30/04/12PRICE SENSITIVE
MSBIntervertebral Disc Repair Phase 2 Trial Update
17/04/12PRICE SENSITIVE
MSBMesoblast Update to Credit Suisse Asia Investment Conference
26/03/12
MSBHalf Yearly Report and Accounts
27/02/12PRICE SENSITIVE
MSB2012 Half Year Results Investor Presentation
27/02/12
MSBFORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER
22/02/12
MSBCompany Secretary Appointment/Resignation
09/02/12
MSBAppendix 3B
09/02/12
MSBFDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes
31/01/12PRICE SENSITIVE
MSBAppendix 4C - quarterly
12/01/12PRICE SENSITIVE
MSBAppendix 3B
12/01/12
MSBPresentation to 30th JP Morgan Healthcare Conference in USA
12/01/12
MSBFORM 604 NOTICE OF CHANGE OF INTERESTS OF SUB HOLDER
09/12/11
MSBResults of Meeting
24/11/11
MSBCorporate Strategy Key to Mesoblast's Success
24/11/11
MSBChairman's Address and CEO's Presentation to Shareholders
24/11/11
MSBPositive Outcome From FDA Meeting For Diabetes Program
22/11/11PRICE SENSITIVE
MSBPresentation to the American Heart Association
15/11/11
MSBPositive Heart Failure Trial Results Presented to AHA
15/11/11PRICE SENSITIVE
MSBPositive Results Using Adult Stem Cells for Type 2 Diabetes
10/11/11PRICE SENSITIVE
MSBAppendix 4C - quarterly
31/10/11PRICE SENSITIVE
MSBResponse to ASX Price Query Letter
28/10/11PRICE SENSITIVE
MSBAnnual Report to shareholders
24/10/11
MSBNotice of Annual General Meeting/Proxy Form
24/10/11
MSBClearance for First Phase 2 Clinical Trial for Eye Diseases
24/10/11PRICE SENSITIVE
MSBLicensing Executives Society Deals of Distinction Award
20/10/11PRICE SENSITIVE
MSBMSB and Lonza form strategic global manufacturing alliance
27/09/11PRICE SENSITIVE
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER
15/09/11
MSBFirst European Trial for Heart Attack Treatment Cleared
05/09/11PRICE SENSITIVE
MSBFull Year Audited Statutory Accounts
31/08/11
MSBMesoblast Management Presentation
24/08/11
MSBMesoblast in Position of Considerable Strength
24/08/11
MSBPreliminary Final Report
24/08/11PRICE SENSITIVE
MSBFirst Minimally Invasive Procedure for Lumbar Disc Repair
22/08/11PRICE SENSITIVE
MSBHeart Failure Trial Selected for AHA Special Session
15/08/11
MSBForm 604 - Notice of change of interests of substantial hold
01/08/11
MSBAppendix 4C - quarterly
01/08/11PRICE SENSITIVE
MSBFDA Clearance for Phase 3 Bone Marrow Transplant Trial
07/07/11PRICE SENSITIVE
MSBAppendix 3B
06/07/11
MSBAmended Change of Director's Interest Notice
04/07/11
MSBChange of Director's Interest Notice
01/07/11
MSBFDA Clears Phase 2 Trial to Treat Degenerative Disc Disease
29/06/11PRICE SENSITIVE
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER
22/06/11
MSBKey Product Franchises Featured at Nomura Asia Equity Forum
14/06/11PRICE SENSITIVE
MSBRevascor Increases Blood Supply to Damaged Heart Muscle
09/06/11PRICE SENSITIVE
MSBMSB to Present at Goldman Sachs Global Healthcare Conference
06/06/11
MSBKey USA Patents Increase Commercial Rights and Indications
24/05/11PRICE SENSITIVE
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER
04/05/11
MSBAppendix 4C - quarterly
02/05/11PRICE SENSITIVE
MSBSandP to remove Tower Australia Group from SP/ASX Indices
18/04/11
MSBMesoblast Included in S and P/ASX 200 Index
18/04/11PRICE SENSITIVE
MSBAppendix 3B
11/04/11
MSBMesoblast Update on Valeant Proposal to Cephalon
07/04/11PRICE SENSITIVE
MSBMesoblast Statement on Valeant Proposal to Cephalon
31/03/11
MSBMesoblast CEO Named BioSpectrum Asia Person of the Year 2011
17/03/11
MSBAppendix 3B
11/03/11
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER
10/03/11
ACL +SandP Announces March SP/ASX Rebalance
04/03/11
MSBAppendix 4D and Half Year Financial Report to 31 Dec 2010
28/02/11PRICE SENSITIVE
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER
17/02/11
MSBChange in substantial holding
15/02/11
MSBCleansing Notice under Section 708A
14/02/11
MSBMesoblast Issues New Equity to Cephalon, Increases Cash
14/02/11
MSBSection 708AA Notice - Cleansing Statement
11/02/11
MSBAppendix 3B
11/02/11
MSBResults of Meeting
09/02/11
MSBMesoblast EGM Speech and Presentation
09/02/11
MSBAppendix 4C - Strong Cash Position
31/01/11PRICE SENSITIVE
MSBResponse to ASX Price Query
13/01/11PRICE SENSITIVE
MSBFORM 604 CHANGE OF INTERESTS OF SUB HOLDER
13/01/11
MSBAlliance Highlighted at JP Morgan Healthcare Conference
12/01/11
MSBCardiac Events, Mortality and Hospitalization Reduced
10/01/11PRICE SENSITIVE
MSBNotice of Extraordinary General Meeting/Proxy Form
07/01/11
MSBInitial Director's Interest Notice
31/12/10
MSBChange of Director's Interest Notice
30/12/10
MSBMesoblast Share Trading Policy Updated
30/12/10
MSBChange in substantial holding
29/12/10
MSBChange in substantial holding
24/12/10
MSBChange of Director's Interest Notice
24/12/10
MSBChange in substantial holding
24/12/10
MSBFORM 603 INITIAL SUB FOLDER
24/12/10
MSBSection 708AA Notice - Cleansing Statement
23/12/10
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.49 		Change
-0.090(5.71%) 		Mkt cap ! $1.113B
Open High Low Value Volume
$1.58 $1.59 $1.47 $7.056M 4.697M

Buyers (Bids)

No. Vol. Price($)
2 3999 $1.48
 

Sellers (Offers)

Price($) Vol. No.
$1.49 46134 7
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
$1.48 		  Change
-0.090 ( 5.55 %)
Open High Low Volume
$1.57 $1.57 $1.47 1111085
Last updated 15.59pm 21/11/2024 ?
MSB (ASX) Chart

Top Stories

Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech

Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.